// App-Quantinova.ai

11068 : A prospective evaluation of cell free DNA (cfDNA) genotyping and circulating tumor cells (CTC) in EGFR mutant NSCLC patients (pts) treated with erlotinib.

Researchers

Presenter

  • Masahiko Yanagita

Principal Investigators

  • Cloud Paweletz

  • Geoffrey R. Oxnard

  • Pasi A. Janne

  • Allison O'Connell

  • David Michael Jackman

  • Yanan Kuang

Medical Centers

  • Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA

  • Dana-Farber Cancer Center Institute, Boston, MADana-Farber Cancer Institute, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Circulating tumor cells

  • Epidermal growth factor receptor

  • Threonine at amino acid position 790

  • Plasma cell-free DNA

Drug/Treatment

  • Erlotinib hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved